Alcobra (ADHD) Presents Positive Results From Phase 2b Study Of Metadoxine Extended Release (MDX) In Adults With Predominantly Inattentive ADHD At American Psychiatric Association Annual Meeting
5/5/2014 9:38:59 AM
NEW YORK, May 5, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced the presentation of data from a successful Phase IIb study of its proprietary drug candidate MDX (Metadoxine Extended Release) in adults with Predominantly Inattentive ADHD (PI-ADHD) at the 167th Annual Meeting of the American Psychiatric Association (APA).1
Help employers find you! Check out all the jobs and post your resume.
comments powered by